Markets
Where we operate.
Amigen operates across five primary regions — MENA, Africa, Southeast Asia, Latin America, and the CIS — bringing proven therapies to patients in markets where the gap between global approval and local access is widest.
Emerging markets are not a single market.
Each country we operate in has its own regulatory authority, its own submission requirements, its own review timelines, and its own market access landscape. What looks like a single region from the outside is, in practice, a portfolio of distinct regulatory environments — each requiring dedicated expertise.
Amigen's value is precisely this: we hold that expertise across multiple markets simultaneously, so our originator partners do not have to build it themselves.
Regional Coverage
Five regions. One partner.
MENA
Middle East & North Africa
MENA is Amigen's primary and most established operating geography. The GCC markets offer high-income patient populations, well-developed healthcare infrastructure, and regulatory authorities that accept EMA, TGA, Health Canada, and other established-market reference data. The broader Levant and North Africa extend our reach into large patient populations with significant unmet need, particularly in oncology and rare diseases.
Africa
Sub-Saharan Africa
Sub-Saharan Africa carries one of the highest global disease burdens, yet the gap between global approval and local patient access is among the widest in the world. The regulatory landscape is evolving rapidly — particularly with the African Medicines Agency framework — and Amigen is building the relationships and local knowledge to operate effectively across this region.
SEAsia
Southeast Asia
Southeast Asia is home to over 700 million people and a rapidly growing pharmaceutical market. Regulatory frameworks across the ASEAN region are increasingly harmonised, and several markets — including Malaysia and Thailand — have well-established pathways for registering therapies already approved in reference markets. Amigen is actively pursuing registration opportunities across the region.
LATAM
Latin America
Latin America represents a substantial and growing pharmaceutical market with a combined population exceeding 650 million. Brazil and Mexico alone account for the majority of regional pharmaceutical spend. Regulatory agencies across the region have established frameworks for accepting reference market approvals, and Amigen is building its registration capability to serve this geography.
CIS
Commonwealth of Independent States
The CIS region encompasses large patient populations with significant unmet need in oncology, rare diseases, and chronic conditions. Several markets — particularly Kazakhstan and the Caucasus states — are actively modernising their regulatory frameworks and offer viable pathways for therapies approved in established markets. Amigen is evaluating registration opportunities across the region.
Regulatory expertise is the product.
In each market we operate, Amigen maintains direct relationships with the relevant national regulatory authority. We understand the submission formats, the review timelines, the query patterns, and the expectations of each agency.
This is not a capability we outsource. It is the core of what we do — and the reason originator companies choose Amigen over building their own local presence.
Looking for a partner in these markets?
If you hold rights to an approved therapy and need a capable, accountable partner to handle registration and commercialisation across MENA, Africa, Southeast Asia, Latin America, or the CIS — we should talk.